Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

Phase 3

Completed

Conditions: HIV-1
HIV Infections
Acquired Immunodeficiency Syndrome

Interventions: Drug: E/C/F/TAF
Drug: Baseline DRV- containing ARV regimen
Drug: DRV

Registration Number: NCT01968551

Lead Sponsor: Gilead Sciences

Brief Summary: The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed dose combination (FDC) plus darunavir (DRV) relative to current antiretroviral regimens (ARV) in virologically suppressed, HIV-1 positive participants with HIV-1 RNA \<50 copies/mL at Week 24.

This study consists of 48 weeks of open-label phase followed by an optional Extension Phase in which all the participants will receive E/C/F/TAF+DRV.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 158

Inclusion Criteria

Ability to understand and sign a written informed consent form
History of at least two prior antiretroviral regimens, and history of resistance to at least two different classes of antiretroviral agents
Plasma HIV-1 RNA levels < 50 copies/mL at screening. Virologically suppressed on the current antiretroviral regimen containing darunavir 600 mg twice a day or 800 mg once daily continuously for ≥ 4 months preceding the screening visit and have maintained documented undetectable plasma HIV-1 RNA levels (< 50 copies/mL) and must have documentation of genotype/phenotype prior to current regimen which shows no darunavir associated resistance mutation.
Currently receiving raltegravir, elvitegravir, or dolutegravir (50 mg once daily, but not twice daily), or have never received integrase inhibitor, or have documentation of genotype/phenotype within 12 months prior to current regimen which must show no evidence of resistance to integrase inhibitors
Normal ECG
Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min according to the Cockcroft Gault formula for creatinine clearance
Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)
Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin
Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm^3; platelets ≥ 50,000/mm^3; hemoglobin ≥ 8.5 g/dL)
Serum amylase ≤ 5 × ULN (individuals with serum amylase > 5 × ULN will remain eligible if serum lipase is ≤ 5 × ULN)
A female individual is eligible to enter the study if it is confirmed that she is:
- Not pregnant or nursing
- Of non-childbearing potential (i.e., women who have had a hysterectomy, have had both ovaries removed or medically documented ovarian failure, or are postmenopausal women > 54 years of age with cessation (for ≥ 12 months) of previously occurring menses), or
- Of childbearing potential and agrees to utilize highly effective contraception methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following the last study drug dose.
- Female individuals who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing.
Male individuals must agree to utilize a highly effective method of contraception during heterosexual intercourse or be non-heterosexually active, or practice sexual abstinence from first dose throughout the study period and for 30 days following the last study drug dose.
Male individuals must agree to refrain from sperm donation from first dose until at least 30 days after the last study drug dose.

Key

Exclusion Criteria

A new AIDS-defining condition diagnosed within the 30 days prior to screening (except CD4 cell count and/or percentage criteria)
Hepatitis B surface antigen (HBsAg) positive
Individuals receiving drug treatment for Hepatitis C, or individuals who are anticipated to receive treatment for Hepatitis C during the course of the study.
Must not have Q151M, T69ins, or > 3 thymidine analogue mutations (TAMS) present on documented historic genotype report
Individuals experiencing decompensated cirrhosis
Females who are breastfeeding
Positive serum pregnancy test
Have an implanted defibrillator or pacemaker
Current alcohol or substance use that may interfere with individual's study compliance
A history of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma.
Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1 visit
Any other clinical condition or prior therapy that would make the individual unsuitable for the study or unable to comply with dosing requirements
Participation in any other clinical trial (including observational trials) without prior approval from the sponsor is prohibited while participating in this trial
Individuals receiving ongoing therapy with any of the disallowed medications, including drugs not to be used with elvitegravir, cobicistat, emtricitabine, TAF, or DRV; or individuals with any known allergies to the study drugs.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 1	E/C/F/TAF	Participants will receive E/C/F/TAF FDC + DRV once daily with food for 48 weeks. Based on safety and efficacy data from Cohort 1 at Week 4, the participants will be randomized into Cohort 2. The participants in Cohort 1 will continue receiving E/C/F/TAF FDC + DRV through 48 weeks.
Cohort 2, Treatment Group 1	E/C/F/TAF	Participants will be randomized to receive E/C/F/TAF FDC+DRV once daily with food for 48 weeks.
Cohort 1	DRV	Participants will receive E/C/F/TAF FDC + DRV once daily with food for 48 weeks. Based on safety and efficacy data from Cohort 1 at Week 4, the participants will be randomized into Cohort 2. The participants in Cohort 1 will continue receiving E/C/F/TAF FDC + DRV through 48 weeks.
Cohort 2, Treatment Group 1	DRV	Participants will be randomized to receive E/C/F/TAF FDC+DRV once daily with food for 48 weeks.
Cohort 2, Treatment Group 2	Baseline DRV- containing ARV regimen	Participants will be randomized to continue on their baseline DRV-containing ARV regimen for 48 weeks.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 24	Week 24	The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in CD4+ Cell Count at Week 48	Baseline; Week 48
Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 48	Week 48	The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Change From Baseline in CD4+ Cell Count at Week 24	Baseline; Week 24

Trial Locations

Locations (62): Pueblo Family Physicians, Ltd.
🇺🇸
Phoenix, Arizona, United States
Pacific Oaks Medical Group
🇺🇸
Beverly Hills, California, United States
Kaiser Permanente
🇺🇸
Hayward, California, United States
Long Beach Education and Research Consultants
🇺🇸
Long Beach, California, United States
Peter J Ruane, MD, Inc.
🇺🇸
Los Angeles, California, United States
Kaiser Permanente Medical Group
🇺🇸
Sacramento, California, United States
Kaiser San Francisco Division of Research
🇺🇸
San Francisco, California, United States
Dupont Circle Physician's Group
🇺🇸
Washington, District of Columbia, United States
Midland Florida Clinical Research Center, LLC
🇺🇸
DeLand, Florida, United States
Therafirst Medical Center
🇺🇸
Fort Lauderdale, Florida, United States
Scroll for more (52 remaining)
Pueblo Family Physicians, Ltd.
🇺🇸Phoenix, Arizona, United States